{
    "nct_id": "NCT06736704",
    "official_title": "A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors",
    "inclusion_criteria": "* Advanced or metastatic solid tumor with an activating PIK3CA mutation.\n* Refractory to or intolerant of available therapies\n* Disease measurable by RECIST 1.1 criteria, or disease evaluable by clinically relevant tumor biomarkers in blood.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Diagnosis of a primary CNS malignancy\n* Active brain metastases or carcinomatous meningitis\n* Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus\n* Inadequate organ function\n* Clinically significant ECG abnormalities, including QTcF â‰¥ 470 ms",
    "miscellaneous_criteria": ""
}